In the States
Select a state to learn more
State Activity
H. 976
2015-2016 Session: Convene: 1/7/15 and Adjourn: 1/4/17
3/10/15: House Referred to committee on Health Care Financing.
BioPharma: NC introduces biosimilar substitution bill as MA looks to amend its law
March 12
North Carolina is jumping on the biosimilar substitution legislation bandwagon with a new bill unveiled this week, while Massachusetts is looking to slightly tweak its law.
Read full article here.
-
Bill Information
Expands the definition of “interchangeable biological product” to include biologics that are determined by FDA to be “therapeutically equivalent” to the prescribed biologic.
-
Archive
Business of Biosimilars and Biobetters
June 16, 2011
September 19-21, 2011 Seaport World Trade Center Boston, MA Read More
Business of Biosimilars and Biobetters
June 16, 2011
September 19-21, 2011 Seaport World Trade Center Boston, MA Read More
4th Annual International Partnering Conference – BioPharm America
June 16, 2011
September 7-9, 2011 Westin Boston Waterfront Boston, MA Read More
4th Annual International Partnering Conference – BioPharm America
June 16, 2011
September 7-9, 2011 Westin Boston Waterfront Boston, MA Read More
The 4th Massachusetts Life Sciences Innovation Day
June 16, 2011
June 2, 2011 Harvard Club of Boston, 374 Commonwealth Avenue Boston, MA Read More
Follow-on Biologics: Current Trends and Insights
June 16, 2011
March 7, 2011 Federal Reserve Bank of Boston; New England Room Boston, MA Read More
MassBio Federal Policy White Paper – 2009
June 16, 2011
MassBio is front and center on Capitol Hill when it comes to advocating for policies that will pave the way for innovation. We fight for the laws and regulations that will speed the development of treatments and cures for Alzheimer’s, Diabetes, HIV/AIDs and other ailments. We work for policies that will help bring those drugs to […]
MassBio – Biosimilars – Our View
June 16, 2011
Drugs developed through biotechnology differ from traditional small molecule chemical drugs. They are “biologics” that are complex medicines manufactured using living organisms. Biosimilars, also known as follow-on biologics are products that are similar to, but not the same as, an innovative new drug. They are not generic drugs, which are products shown to be the […]
Massachusetts Government – Life Sciences
June 16, 2011
From pharmaceuticals and medical devices to diagnostics and biotechnology, the life sciences are a cornerstone of Massachusetts’ innovation economy. Massachusetts is a global leader in the life sciences, thanks to our world-class academic institutions and medical centers, our talented workforce, and our industry-sector leading companies. Read More
Massachusetts Government – Life Sciences
June 16, 2011
From pharmaceuticals and medical devices to diagnostics and biotechnology, the life sciences are a cornerstone of Massachusetts’ innovation economy. Massachusetts is a global leader in the life sciences, thanks to our world-class academic institutions and medical centers, our talented workforce, and our industry-sector leading companies. Read More